The tumorigenic and metastatic properties of rat bladder carcinoma NBT-II cells transfected with a cDNA encoding the 24 kD nuclear isoform of human ®broblast growth factor-2 (FGF-2) were analysed and compared with those cells producing the 18 kD cytoplasmic isoform FGF-2. In transfected clones, 24 kD FGF-2 was found in the nucleus, and no FGF-2 was secreted. RT ± PCR analysis showed no upregulation of FGF-2-speci®c receptor FGFR2c expression in these proliferating transfected cells. A shorter latency period for in vivo tumor formation and abundant spontaneous lung metastases were only seen if nuclear FGF-2-producing cells were injected subcutaneously into nude mice. Intravenous injection of 24 kD FGF-2-producing cells led to extensive experimental lung metastases whereas injection of control NBT-II cells or 18 kD FGF-2-producing cells did not. As FGF-2-producing cells have no speci®c FGF-2 receptors, our results suggest that the 24 kD FGF-2 has nuclear targets, and activates metastatic property of carcinoma cells via a mechanism other than the conventional FGF receptor-mediated signaling pathway.
Introduction
Fibroblast growth factor-2 (FGF-2) is a multifunctional protein with well studied mitogenic and angiogenic properties (Basilico and Moscatelli, 1992; Burgess and Maciag, 1989; Fernig and Gallagher, 1994; Mason, 1994) . Several FGF-2 isoforms have been identi®ed; higher molecular weight (21, 22, 24 and 34 kD) and lower molecular weight (18 kD) FGF-2 isoforms are produced from dierent initiation codons (Florkiewicz and Sommer, 1989; Prats et al., 1989; Arnaud et al., 1999) . Only the higher molecular weight isoforms with a nuclear localization signal (NLS) are translocated to the nucleus (Bugler et al., 1991) , and there have been several studies of the nuclear translocation of the FGF-2 protein (Bouche et al., 1987; Florkiewicz et al., 1991; Renco et al., 1990; Tessler and Neufeld, 1990) . Nuclear translocation of peptide growth factors has been reported in various types of cell (Levine and Prystowsky, 1995) , but such translocation is not necessarily linked to the functions of nuclear growth factors. The functional dierences between nuclear and cytoplasmic FGF-2 isoforms are unclear. The NLS-dependent nuclear translocation of high molecular weight FGF-2 suggests that this isoform of FGF-2 has an unknown biological role dierent from that of cytoplasmic FGF-2. Several studies investigated the possible functions of the various FGF-2 isoforms. Endogenous selective expression of the high molecular weight isoform of FGF-2 induces immortalization in endothelial ABAE cells (Couderc et al., 1991) , morphological changes and growth in pancreatic acinar AR4-2J cells (Estival et al., 1993) and NIH3T3 cells (Bikfalvi et al., 1995; Quarto et al., 1991) in low-serum or serum-free medium, and binucleation of cardiac myocytes (Pasumarthi et al., 1995) . Cells with a transformed phenotype are potentially tumorigenic and the role of FGF-2 in tumorigenicity is thought to be associated with cellular transformation (Basilico and Moscatelli, 1992) . The expression of all FGF-2 isoforms stimulates endothelial HEC-1-B (Coltrini et al., 1995) and neural cell proliferation (Joy et al., 1997) , and in vivo tumorigenicity in ABAE (Couderc et al., 1991) and NIH3T3 cells (Quarto et al., 1991) . However, no one particular isoform of FGF-2 can be considered to be fully responsible for tumorigenicity.
In the rat bladder carcinoma NBT-II cell experimental model, the production of low molecular weight (18 kD) FGF-2 induces angiogenic tumors, but does not result in high level of tumorigenicity (Jouanneau et al., 1997) . In contrast we show herein that production of the 24 kD FGF-2 alone results in NBT-II cells becoming tumorigenic and lung metastatic. Thus, regulation of the lung metastasis of 24 kD FGF-2-producing cells may be controlled by FGF-2 in the nucleus, with the possible involvement of speci®c nuclear targets.
Results

Expression of 24 kD FGF-2
NBT-II cells were transfected with an expression vector encoding the 24 kD FGF-2. This plasmid was designed to produce exclusively the 24 kD FGF-2, and the production of other isoforms of FGF-2 was prevented by introducing point mutations into each of the corresponding start codons. G418-resistant clones were selected for the production of 24 kD FGF-2, and FGF-2 mRNA was detected by Northern blot analysis (data not shown). Most, but not all, of the transfected cells were epithelial-like in morphology, similar to parental NBT-II cells and 18 kD FGF-2-producing bGF22 cells (Jouanneau et al., 1997) . Three clones, NLS20 (epithelial), NLS35 (epithelial) and NLS42 (®broblast-like) were chosen for further study.
The presence of the FGF-2 protein in nuclei was con®rmed by immuno¯uorescence staining using a monoclonal antibody (Figure 1 ). Control NBT-II cells did not react with the antibody ( Figure 1A ) and 18 kD FGF-2-producing bGF22 cells only gave a signal in the cytoplasm ( Figure 1B) . A strong signal was detected in the nucleus of NLS20 ( Figure 1C ) and NLS35 ( Figure  1D ) clones with epithelial morphology and in ®broblast-like NLS42 cells ( Figure 1E ). The intensity of FGF-2 immunostaining was higher in the nuclei of subcon¯uent cells than in those of con¯uent cells (data not shown).
FGF-2 protein was recovered from nuclear extracts of subcon¯uent NLS cells by incubation with heparinsepharose gel, and was analysed by Western blotting. The 24 kD FGF-2 was present in the nuclear fraction of transfected cells (Figure 2 , upper panel, lanes 1, 2 and 3), and a faint lower molecular weight band was also visible in the nuclear fraction. A very small amount of 24 kD FGF-2 protein was detected in the cytoplasmic fraction ( 
Tumorigenic properties of 24 kD FGF-2-producing cells
It has been shown that 18 kD FGF-2-producing cells are no more tumorigenic than control NBT-II cells in nude mice, with a latency period for in vivo tumor induction of more than 6 weeks (Jouanneau et al., 1997) . If NLS cells were injected subcutaneously into nude mice, the tumor latency period decreased for NLS42 and NLS20 cells, but not for NLS35 cells ( Cells from lung metastases derived from NLS20 tumors (NLS20-S5P) and NLS42 tumors (NLS42-S32P) were grown in culture and used to inoculate nude mice. These lung-derived cells have enhanced tumorigenic potential, as the lag time for tumor induction was 50% shorter than that of the parental NLS cells, and also their lung metastatic potential was increased ( Figure 3 , panel B). However, morphological appearance in vitro and biochemical properties such as 24 kD FGF-2 production and its nuclear localization ( Figure 1F ) were similar for cells derived from lung metastases and parental NLS cells.
We then tested the lung-colonizing capacity in vivo of NLS cells and lung-derived tumor cells, by intravenous injection into either the tail vein or the ocular sinus of nude mice. A large number of small foci were observed in mouse lungs 2 weeks after the injection of NLS cells or their metastatic derivatives, but no metastatic foci were observed 2 weeks after injection of control NBT-II cells or 18 kD FGF-2-producing cells (data not shown). Expression of FGF-2-speci®c receptors in 24 kD FGF-2-producing cells
We investigated whether the biological properties of NLS cells were mediated by an autocrine or paracrine action of 24 kD FGF-2, by studying the expression of FGF-2-speci®c receptors, by RT ± PCR. Proliferating parental NBT-II cells do not have speci®c receptors for FGF-2 (Savagner et al., 1994) because they only express the FGFR2b spliced variant of FGFR2, which does not bind FGF-2. In NLS cells (NLS20, NLS35, NLS42, NLS20-S5P and NLS42-S32P), the FGF-2 receptor spliced variant, FGFR2c, was not detected by PCR, and only FGFR2b was detected, as in parental NBT-II cells and 18 kD FGF-2-producing cells (data not shown).
Discussion
Production and distribution of the 24 kD FGF-2 protein
Western blot analysis of the FGF-2 produced in NLS cells showed that a major band was present at the expected molecular weight (24 kD) in the nuclear fraction, consistent with nuclear immunostaining results for these cells. A lower molecular weight band was also detected in the nuclear fraction, but it is unlikely to correspond to the low molecular weight FGF-2 isoform (18 kD) because the NLS cells were designed to produce 24 kD FGF-2 exclusively, and no endogenous 18 kD or 24 kD FGF-2 is produced by untransfected NBT-II. A loss of FGF-2 protein during cell fractionation has been reported (Gualandris et al., 1993; Pintucci et al., 1996) , suggesting that the lower molecular weight band may be generated by proteolysis of 24 kD FGF-2, during or after puri®cation. Heterogeneous immunostaining and the more intense FGF-2 signal in subcon¯uent NLS cells than in con¯uent cells suggest the cell-cycle and/or celldensity-dependent nuclear accumulation of endogenous 24 kD FGF-2 in NLS cells. Such endogenous cell cycle dependent FGF-2 nuclear accumulation has been observed in astrocytes (Hill and Logan, 1992) .
Role of nuclear FGF-2 in tumorigenicity
This study indicates that the presence of 24 kD FGF-2 in nuclei may result in tumorigenic properties with no obvious correlation with cell morphology. Both epithelial (NLS20) and ®broblast-like (NLS42) cells 24 kD FGF-2-producing clones were more tumorigenic in vivo than the epithelial 18 kD FGF-2-producing cells (Figure 3, panel A) . Another epithelial cell type, NLS35 was no more tumorigenic than control NBT-II cells, suggesting that there is no direct correlation between high level of tumorigenicity and 24 kD FGF-2 production in the NBT-II cell system. Parental NBT-II cells have no speci®c FGF-2 receptors on their surface (Savagner et al., 1994) , and there is no detectable upregulation of expression of the FGF-2-speci®c receptor splice variant, FGFR2c, in NLS cells. The 24 kD FGF-2 was not secreted by the NLS cells. Thus the high level of tumorigenicity of NLS cells does not result from the autocrine action of FGF-2.
Tumor angiogenesis is not critical in NLS cell-derived tumor
Histological analysis and von Willebrand Factor staining were carried out on frozen sections of tumor developed with 24 kD FGF-2-producing cells and control NBT-II cells. The two types of tumor had similar vascularization patterns (data not shown), very unlike that of highly angiogenic 18 kD FGF-2-producing cell-derived tumors (Jouanneau et al., 1997) . As 18 kD FGF-2-producing cells secrete detectable amounts of biologically active 18 kD FGF- . Numbers of mice tested were as follows; NBT-II B43: 185; bGF22: 35; NLS20: 10; NLS35: 10; NSL42: 26; NLS20-S5P: 10; NLS42-S32P: 10
Nuclear 24 kD FGF-2 and metastasis M Okada-Ban et al 2, extensive tumor vascularization is attributed to angiogenic activity of the 18 kD FGF-2. Angiogenesis is essential for tumor growth, but rapidly growing NLS tumors were less vascularized than tumors obtained with 18 kD FGF-2-producing cells. Thus, the 24 kD FGF-2 does not act as a tumor angiogenic factor, but rather as a signaling molecule, increasing in vivo tumorigenicity.
Role of nuclear FGF-2 in cancer cell metastasis
Lung metastasis of NBT-II-derived carcinoma cells is speci®cally associated with the production of the FGF-2 24 kD isoform, because 18 kD FGF-2-producing cells did not give rise to metastatic foci in the lung when primary tumors reached the same size. Micrometastases of NBT-II carcinoma cells and of transfected NBT-II cells, producing FGF-1 , FGF-4 (Jouanneau et al., 1995) , TGFa (Jouanneau, unpublished data) or HGF/SF (Bellusci et al., 1994) are commonly found in the lymph nodes, but never in the lungs or in other organs .
The lung colonizing capacity of NLS cells was assayed in experimental metastasis by intravenous injection in nude mice. We found that 24 kD FGF-2-producing cells survived in the bloodstream and colonized the lungs; in the same experimental conditions, parental NBT-II cells and 18 kD FGF-2 producing cells did not give rise to lung foci.
NLS cells derived from lung metastatic foci were more tumorigenic and lung metastatic than their parental cells, even though their morphological and biochemical characteristics were similar. The greater tumorigenicity and metastatic properties of such lungderived cells may be due to in vivo selection. The tumorigenicity and lung metastatic potentials of 24 kD FGF-2-producing cells are not closely correlated because, for example, NLS35 cells were no more tumorigenic than control NBT-II cells but did produce numerous lung metastatic foci in nude mice.
The metastatic potential of NLS cells cannot be predicted from cellular morphology, because all the NLS clones tested gave similar level of lung metastasis despite being morphologically dierent. These dierences may be due to dierence in metalloproteinase (MMP) production in the cells. However, using zymography we found that the gelatinase activities present in secretions from NBT-II cell transfected with FGF-1 (®broblast-like morphology) and from NLS cells were similar (unpublished date). Nuclear FGF-2 probably stimulates or initiates metastatic signaling the mechanism of which is unknown.
Impact of endogenous nuclear FGF-2 production
We have clearly demonstrated the importance of the 24 kD nuclear isoform of FGF-2, which confers lung metastatic properties on NBT-II carcinoma cells and also, in some but not all cases, increases their tumorigenicity. The biological activities of most growth factors are thought to be expressed via binding to their receptors, but our experimental system excludes such an autocrine/paracrine mechanism for FGF-2.
The lung metastatic properties of carcinoma cell are clearly associated with the endogenous production of nuclear FGF-2; cytoplasmic FGF-2 production had no eect. Our results provide evidence for a novel FGF-2 biological activity that may be involved in the induction of metastatic and tumorigenic potential in carcinoma cells, because this nuclear growth factor may stimulate novel signaling pathways or transcriptional activities (Nakanishi et al., 1992; Bonnet et al., 1996) . Molecular mechanisms for tumor metastasis are, in many cases, attributed to a limited number of putative metastatic markers (Sidransky, 1997) . FGF-2 has not previously been considered to be such a marker, but our study indicates that nuclear FGF-2 is a potential metastasis inducer in carcinoma cells. Screening for possible nuclear targets of FGF-2 and its investigation of functions in tumor metastasis induction are underway. Our experimental system provides an in vivo model for the study of FGF-2-induced tumor progression and metastasis, independent of the conventional FGF-2 receptor-mediated signaling pathway.
Materials and methods
Cells
NBT-II cells, which were originally isolated from a chemically-induced rat bladder carcinoma (Toshima et al., 1971) , were provided by Professor M Mareel (University of Gent, Belgium). Cells from NBT-II clone 19 were used . Cells were routinely cultured in monolayers in Dulbecco's modi®ed Eagle's minimal essential medium with 10% heat-inactivated fetal calf serum with 1% glutamine and antibiotics (complete medium). The cells were grown at 378C in a humidi®ed atmosphere containing 6% CO 2 and were routinely cultured after trypsin treatment (0.05% trypsin and 0.02% ethylenediamine tetraacetic acid w/v). NBT-II B43 cells, which express b-galactosidase, were used as controls .
Expression plasmid for nuclear FGF-2 and transfection
The pRFE-neo biscistonic expression vector, a gift from Drs B Bugler and H Prats (INSERM U397, Toulouse, France) , contains the neomycin resistance (Neo R ) gene and a human FGF-2 cDNA under control of the CMV promoter such that it produces only the 24 kD FGF-2. NBT-II cells were transfected by the calcium-phosphate coprecipitation method (Graham and Van der Eb, 1973) with 10 mg of the pRFE-neo expression plasmid. The parental cells were seeded in 10 cmdiameter plastic culture dishes with 0.8610 6 cells/dish, 24 ± 36 h before transfection. Transfected cells were incubated for 24 h, treated with trypsin and cultured at 1 : 4 dilution in culture medium containing the neomycin analog G418 (400 mg/ml) (selective medium). After 2 ± 3 weeks, G418-resistant colonies were picked and ampli®ed using the selective medium for the ®rst two passages. Selected clones were grown in complete medium from the 3rd passage, and 24 kD FGF-2-producing clones were renamed as NLS cells.
Antibodies and immuno¯uorescence analysis
Anti FGF-2 monoclonal antibody was purchased from Transduction Laboratories (USA). Cells were grown on thin glass coverslips for 1 ± 3 days and ®xed in 4% paraformaldehyde in phosphate-buered saline (PBS). Fixed cells were permeabilized by incubation with PBS containing 0.1% Triton X-100 for 20 min at room temperature, followed by Nuclear 24 kD FGF-2 and metastasis M Okada-Ban et al washing and blocking with 5% normal serum in PBS. Cells were incubated with FGF-2 antibody (1 : 25 in dilution in PBS) overnight at 48C in a humid atmosphere, washed with washing buer (PBS containing 0.25% Tween-20, w/v) several times, and stained with¯uorescent secondary antibody for 1 h at room temperature. They were then rinsed with washing buer and mounted.
Isolation of nuclear fraction and detection of FGF-2 protein
Cell pellets were collected by trypsin treatment of subconuent cells. They were washed thoroughly with PBS, centrifuged, suspended in 100 mM Tris-HCl pH 7.5, 1 mM ethylenediamine tetraacetic acid, 10 mM NaCl, 1 mM phenylmethyl-sulfonyl¯uoride, 10 mg/ml leupeptin, 10 mg/ml pepstatin-A and homogenized with a glass homogenizer for 30 strokes. Cell nuclei were separated by centrifugation at 2000 g through a sucrose and were solubilized in PBS containing 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate, 1 mM phenyl-methyl-sulfonyl uoride, 10 mg/ml leupeptin, 10 mg/ml pepstatin-A. They were then centrifuged at 5000 g for 10 min to remove insoluble substances. Nuclear fractions (soluble) were incubated with heparin-sepharose (Pharmacia Biotech, Uppsala, Sweden) to recover FGF-2 protein. Fixed proteins were solubilized with reducing sample buer, and detected after SDS ± PAGE by Western blot analysis with a peroxidase-linked secondary antibody (antibody dilution 1 : 250). FGF-2 was determined semiquantitatively by comparison of the signal with that of control FGF-2 protein.
PCR-based detection of the FGF receptor FGF receptors were detected by RT ± PCR, as described in a previous report (Savagner et al., 1994) . Brie¯y, total RNA was extracted from NBT-II cells and transfected cells; cDNA was obtained by reverse transcription used as a template for PCR, using speci®c oligomeric DNA primers to distinguish the alternative spliced variants of FGFR2, FGFR2b and FGFR2c. Synthetic oligomeric DNA primers were purchased from Genset (France), and were based on previously determined sequences (Savagner et al., 1994) .
In vivo experiments
Untransfected NBT-II cells or FGF-2-producing cells (3.5610 6 cells) were injected subcutaneously into the¯ank of 6-week-old female Swiss nude mice (nu/nu, Ia Credo, Les Oncins, France). Series of ®ve animals were used in each experiment. Tumor growth was assessed twice a week and spheroid volume was calculated from the measurements of two perpendicular dimensions. When tumor volume reached approximately 2000 mm 3 , tumors and lungs were aseptically removed and fragments grown in culture, or treated with Bouin ®xative solution for anatomical and pathological analysis. Experimental metastasis was obtained by intravenous injection of 1.75610 6 cells into either the tail vein or the ocular sinus. Lungs were removed 2 weeks after injection.
Abbreviations FGF, ®broblast growth factor; FGFR, ®broblast growth factor receptor
